Search results for: Health Policy and Regulation
Filter search results
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
1 August 2015
…and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations….
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
…challenge of providing optimal pricing for, and reimbursement of, multi-indication drugs and (ii) the feasibility of implementing MIP in the UK’s National Health Service (NHS). The workshop agreed that relative…
Assessing Trends in SMC Advice Decisions (October 2009- September 2015)
1 February 2016
…an orphan drug), the introduction of Patient and Clinical Expert (PACE) groups, and the increased use of Patient Access Schemes (PAS). We find that there has been an increase in…
An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
1 December 2016
…and June 2016 nearly a quarter (89 of 407) of all National Institute for Health and Care Excellence (NICE)-reported decisions for individual technologies assessed through their technology appraisal (TA) process…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
…in the UK. We also show that there is both variation across agencies and variation across therapeutic classes in terms of adoption decisions and access across England, Scotland and Wales….
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
1 January 2018
The CRA Report has an underlying assumption that the EU is as globally competitive in generics and biosimilars as it is in innovative products. There is no evidence to support…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
The notion that the price of a medicine should be linked in some way to value it generates for patients and the health system is generally accepted. Yet, how can…
Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
1 July 2018
…therapy: tyrosine-kinase inhibitors (TKIs) and PD-1/PD-L1 inhibitors and show how competing products and competing indications have developed over time. In the case of the PD-1/PD-L1 inhibitors additional indications are currently…
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
…a way to adjust the established cost-effectiveness thresholds (CETs) by several factors, including, the size of patient populations and the costs of research and development (R&D). Once adjusted, CETs sustain…